Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection

Lamfers, Martine L.M.; Idema, Sander; Milligen, Florine Van; Schouten, Tabitha; Valk, Paul van der; Vandertop, W. Peter; Dirven, Clemens; Noske, David P.

doi:10.1016/j.canlet.2008.08.035

Cited by 52 publications

(33 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Usually, infection by an adenoviral vector encoding apoptosis-inducing molecules can induce potent inflammatory reactions that may contribute to regression of malignancies. 47,48 The other important finding of this study was that Ad/AFPtBid did not produce any obvious side effects in term of the activity of mice, the blood cell number, liver and renal functions. However, data obtained by Choi et al 49 showed a dose-dependent toxicity response to systemically administered adenoviral vectors.…”

Section: Discussionmentioning

confidence: 59%

Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice

Chen

Yip

et al. 2010

Gene Ther

View full text Add to dashboard Cite

Previous studies have shown that the application of Ad/AFPtBid significantly and specifically killed hepatocellular carcinoma (HCC) cells in culture and subcutaneously implanted in mice. This study was to test the therapeutic efficacy of Ad/AFPtBid in an orthotopic hepatic tumor model. Four weeks after implantation of tumor cells into the liver, nude mice were treated with Ad/ AFPtBid alone or in combination with 5-fluorouracil (5-FU). Serum a-fetoprotein (AFP) was measured as a marker for tumor progression. The results showed that Ad/AFPtBid significantly inhibited Hep3B tumor growth. Ad/AFPtBid and 5-FU in combination was more effective than either agent alone. Tumor tissues of Ad/AFPtBid alone or combination treatment groups showed a decrease in cells positive for proliferation cell nuclear antigen, but an increase in apoptosis. Ad/AFPtBid did not suppress the hepatic tumor formed by non-AFP-producing hepatoma SK-HEP-1 cells or colorectal adenocarcinoma DLD-1 cells. The survival rate was higher in mice treated with Ad/AFPtBid plus 5-FU than those treated with either agent alone. No acute toxic effect was observed in mice receiving Ad/AFPtBid. Collectively, Ad/AFPtBid can specifically target and effectively suppress the AFP-producing orthotopic liver tumor in mice without obvious toxicity, indicating that it is a promising tool in combination with chemotherapeutic agents for treatment of AFP-producing HCC.

show abstract

Section: Discussionmentioning

confidence: 59%

Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice

Chen

Yip

et al. 2010

Gene Ther

View full text Add to dashboard Cite

show abstract

“…Reprogramming memory may suggest incomplete reprogramming of iPSCs, while if pPiPSCs could retain the properties of original cells that could be beneficial in clinical practice or basic research, they may have useful applications. ADSCs possess the capacity of multipotency (Oswald et al 2004, Lindroos et al 2011, high activity of secretion (Spaggiari et al 2009, Nguyen et al 2010, homing (Lamfers et al 2009), and immune modification (Yanez et al 2006), and have been widely used in cell replacement therapy (CRT) and clinical research (Trivedi et al 2008, Ichim et al 2010. We questioned as to whether pPiPSCs retained these favorable characteristics after reprogramming.…”

Section: Discussionmentioning

confidence: 99%

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Wei¹,

Li²,

Zhang³

et al. 2015

Reproduction

View full text Add to dashboard Cite

Partially reprogrammed induced pluripotent stem cells (PiPSCs) have great potential for investigating reprogramming mechanisms and represent an alternative potential material for making genetically modified animals and regenerative medicine. To date, PiPSCs have scarcely been reported in detail when compared with mice and humans. In this study, we obtained PiPSCs from porcine adipose-derived stem cells (pADSCs) by ectopic expression of human transcription factors (OCT4, SOX2, c-MYC, and KLF4) in feeder-free condition. The morphology and proliferation activity of porcine PiPSCs (pPiPSCs) were similar to those of porcine fully reprogrammed iPSCs (pFiPSCs); furthermore, pPiPSCs expressed higher levels of the typical surface molecules (CD29) found in pADSCs. However, pPiPSCs were negative for key proteins (NANOG) connected with stemness and possessed lower differentiation ability in vivo and in vitro. When differentiationinhibiting factors were withdrawn, pPiPSCs-derived cells (pPiPSC-DCs) showed similar features to pADSCs in many aspects, including proliferation, differentiation, and immunosuppression. When both types of cells were used to produce cloned embryos, we found that the blastocyst formation rate of 19DC (one of the pPiPSC-DC cell lines)-derived cloned embryos was obviously higher than that of others. The total cell number of 19DC-derived blastocysts was significantly higher than the 30DC (one pFiPSC-DC cell line)-derived blastocysts. In all, through limited differentiation ability, the proliferation activity of pPiPSCs is similar to that of pFiPSCs, and pPiPSCs can retain several of the features of pADSCs, which are beneficial to cell therapy. Furthermore, the differentiation of pPiPSCs is more favorable for producing high-quality reconstructed embryos. Free Chinese abstract: A Chinese translation of this abstract is freely available at

show abstract

“…Another virus with broad application where engineered MSCs act as carriers is Herpes simplex virus type 1 (HSV-1). To control Ad5's limitations, modifications of adenoviruses have been researched with great attention put on chemical conjugation [56], fiber-modification of adenoviruses [57], etc. Lately, Menotti et al, have investigated possible modifications and designed HER2 (human epidermal growth factor receptor 2)-retargeted HSV-1 vectors by using the process of conjugation with a single-chain antibody (scFv) [58].…”

Section: Mscs Engineered As Anticancer Drug De-livery Systemsmentioning

confidence: 99%

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Ackova¹,

Kanjevac²,

Rimondini³

et al. 2016

PRA

View full text Add to dashboard Cite

Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses' directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.

show abstract

Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection

Cited by 52 publications

References 44 publications

Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice

Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Contact Info

Product

Resources

About